Smoking and Risk of Coronary Heart Disease Among Women With Type 2 Diabetes Mellitus

ORIGINAL INVESTIGATION Smoking and Risk of Coronary Heart Disease Among Women With Type 2 Diabetes Mellitus Wael K. Al-Delaimy, MD, PhD; JoAnn E. Manson, MD, DrPH; Caren G. Solomon, MD, MPH; Ichiro Kawachi, MD, PhD; Meir J. Stampfer, MD, DrPH; Walter C. Willett, MD, DrPH; Frank B. Hu, MD, PhD Background: Although the association between smoking and increased risk of coronary heart disease (CHD) is well established in the general population, this relationship is less well-defined among individuals with diabetes. Objective: To assess the relationship between cigarette smoking and risk of CHD among women with type 2 diabetes mellitus in the Nurses Health Study cohort. Methods: The Nurses Health Study, a prospective cohort study of 121700 US female registered nurses surveyed in 11 states and followed up from July 1, 1976, through July 1, 1996, involved a total of 6547 women diagnosed as having type 2 diabetes mellitus. Incident cases of CHD were our main outcome measure in this study. Results: We documented 458 incident cases of CHD (200 fatal CHD-related cases and 258 nonfatal myocardial infarctions) during 20 years (68227 person-years) of followup. We found a dose-response relationship between current smoking status and risk of CHD among diabetic women. Compared with never smokers, the relative risks (RRs) for CHD were 1.21 (95% confidence interval [CI], 0.97-1.51) for past smokers, 1.66 (95% CI, 1.10-2.52) for current smokers of 1 to 14 cigarettes per day, and 2.68 (95% CI, 2.07-3.48) for current smokers of 15 or more cigarettes per day in multivariate analyses (P.001 for trend). The multivariate RR of CHD among diabetic women who had stopped smoking for more than 10 years was similar to that among diabetic women who were never smokers (RR, 1.01; 95% CI, 0.73-1.38). In secondary analyses involving diabetic and nondiabetic women, the multivariate-adjusted RR of CHD for those with diabetes who currently smoked ( 15 cigarettes per day) compared with those who never smoked was 7.67 (95% CI, 5.88-10.01). Conclusions: Cigarette smoking is strongly associated with an increased risk of CHD among women with type 2 diabetes mellitus. Furthermore, quitting smoking seems to decrease this excess risk substantially; women with diabetes should be strongly advised against smoking. Arch Intern Med. 2002;162:273-279 From the Departments of Nutrition (Drs Al-Delaimy, Willett, and Hu), Epidemiology (Drs Manson, Stampfer, and Willett), and Health and Social Behavior (Dr Kawachi), Harvard School of Public Health, Boston, Mass; and the Channing Laboratory (Drs Manson, Kawachi, Stampfer, and Willett) and the Divisions of Preventive Medicine (Dr Manson) and General Medicine and Women s Health (Dr Solomon), Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston. DIABETES CONFERS a substantially increased risk of coronary heart disease (CHD), 1-3 especiallyamong women. 4,5 Smoking is an established risk factor for CHD among the general population. 6 However, the magnitude of the association between smoking and CHD risk among diabetic women has not been well studied. 7 Furthermore, the impact of quitting smoking, using quantitative measures of quitting history, on this CHD risk has not been investigated fully. Therefore, we assessed the relationships of smoking and quitting smoking to the risk of CHD among diabetic women in the Nurses Health Study cohort during 20 years of follow-up. RESULTS At baseline, 1754 women reported physician-diagnosed diabetes at 30 years or older. During the follow-up, an additional 4793 women reported a diagnosis of diabetes. During 68227 person-years of follow-up among these women, we documented 458 incident cases of CHD (200 fatal CHD-related cases and 258 nonfatal MI cases) from 1976 to 1996. Table 1 shows the characteristics of the diabetic women in relation to their smoking habits in 1986. Current smokers were leaner and more likely to consume alcohol. Past smokers had a higher prevalence of diagnosed high blood pressure. Current smokers were less likely to use vitamin E supplementation. The risk of CHD increased monotonically with greater smoking (Table 2). Compared with never smokers, the RRs for CHD were 1.21 for past smokers, 1.66 for current smokers of 1 to 14 cigarettes per day, and 2.68 for current smokers of 15 or more cigarettes per day in the multivariate analysis. The association for non- 273

SUBJECTS AND METHODS STUDY POPULATION The Nurses Health Study was established in 1976, when 121700 US female registered nurses aged 30 to 55 years who each resided in 1 of 11 states completed a mailed questionnaire regarding medical history and lifestyle factors. This information has been updated every 2 years. The population for this analysis included women who were diagnosed as having type 2 diabetes mellitus at baseline or during follow-up between July 1, 1976, and July 1, 1996. ASSESSMENT OF SMOKING Smoking status was assessed on each biennial questionnaire. Participants were classified as current, past, or never smokers. Current smokers were categorized into those who smoked 1 to 4, 5 to 14, 15 to 24, 25 to 34, 35 to 44, or 45 or more cigarettes per day. In this study, these categories were collapsed into 1 to 14 and 15 or more cigarettes per day because of the small number of cases. For time since quitting, former smokers were categorized as having stopped smoking for 1 to 5, 6 to 10, 11 to 15, and more than 15 years. The last 2 categories were also combined to assess the effect of quitting for more than 10 years. Coronary heart disease related events were allocated to the smoking exposure status defined on the most recent questionnaire. DOCUMENTATION OF DIABETES When a participant reported a diagnosis of diabetes, we mailed her a supplementary questionnaire requesting information on the details of the diagnosis (ie, diagnostic tests, symptoms, and year of diagnosis) and therapy (insulin or oral hypoglycemic treatment). Using the National Diabetes Data Group criteria, 8 diabetes was considered confirmed if the questionnaire indicated one of the following: (1) classic symptoms (excessive thirst, polyuria, weight loss, and hunger) associated with an elevated plasma glucose level (fasting value, 141 mg/dl [ 7.8 mmol/l]; random value, 200 mg/dl [ 11.1 mmol/l]; or a 2-hour postglucose challenge value of 200 mg/dl [ 11.1 mmol/l]); (2) there were no symptoms, but at least 2 plasma glucose values were elevated by the criteria previously described on different occasions; or (3) treatment with a hypoglycemic medication (insulin or an oral hypoglycemic agent). We depended on self-reported information for the diagnosis of diabetes by these nurses, but validated the reports in a random sample of women by obtaining their medical records. Among 84 women classified by the supplementary questionnaire as having type 2 diabetes mellitus, 71 provided permission to review their medical records and 62 had records available. An endocrinologist (J.E.M.) blinded to the information reported on the supplementary questionnaire reviewed the records according to the National Diabetes Data Group criteria. 8 The diagnosis of type 2 diabetes mellitus was confirmed in 61 (98%) of the 62 women. 9 Those with diabetes diagnosed before the age of 30 years (most likely type 1 diabetes mellitus) or a previous diagnosis of cancer or cardiovascular disease (CVD) were excluded from all analyses. In the primary analyses, selfreported diabetes was used to define the analytic cohort (n=6547 diabetic women). Secondary analyses including only diabetic cases confirmed by the supplementary questionnaire (n=4863) yielded similar results. DIAGNOSIS OF CHD The primary end point in our analysis was incident CHD (including nonfatal myocardial infarction [MI] and fatal CHD). We analyzed stroke and total CVD (CHD and stroke) as secondary end points. All CVD-related cases were included in the analysis if they were diagnosed after the 1976 questionnaire, and after the diagnosis of diabetes. Women who reported a nonfatal MI were asked permission to review their medical records, which were used to confirm the diagnosis according to the World Health Organization diagnostic criteria (ie, symptoms plus either cardiac enzyme level elevations or diagnostic electrocardiographic changes). Physicians blinded to exposure status conducted the record reviews. Infarctions were classified as probable if a patient required hospital admission, and confirmatory information was obtained by interview or letter without medical records. All confirmed and probable nonfatal MI cases were included in the analyses. fatal MI was somewhat stronger than for fatal CHD (Table 2). Further adjustment for vitamin E supplement use did not alter the results. Current smokers had an RR of 2.17 of developing CHD compared with nonsmokers (never or past smokers) in multivariate-adjusted analyses, and the CHD risk attributable to smoking in this population was 19% (current smoking prevalence, 20%). Analyses stratified by body mass index, parental history of MI, postmenopausal hormone use, diabetes medication, duration of diabetes, and alcohol use showed consistent associations between smoking and risk of CHD (Table 3). This association was stronger among women younger than 60 years than among women 60 years and older. Past smokers were divided into those who stopped smoking for more than 15, 11 to 15, 6 to 10, and 1 to 5 years (Figure 1). The multivariate RR of CHD among diabetic women who had stopped smoking for more than 10 years was similar to that among diabetic women who were never smokers. Women who had stopped smoking within the past 10 years still had an increased risk (RR, 1.32 [95% CI, 0.96-1.84] for those who quit for 6-10 years; and RR, 1.40 [95% CI, 1.04-1.88] for those who quit for 1-5 years) compared with the never smokers. Nevertheless, the latter 2 groups of past smokers were still at a lower risk compared with current smokers. In secondary analyses, we examined smoking in relation to the risk of stroke and total CVD (stroke and CHD). The multivariate RRs for stroke were 0.69 (95% CI, 0.48-1.00) among past smokers, 1.04 (95% CI, 0.50-2.17) among current smokers of 1 to 14 cigarettes per day, and 1.84 (95% CI, 1.21-2.81) among current smokers of 15 or more cigarettes per day (P=.004 for trend). The multivariate RRs of CVD were 1.03 (95% CI, 0.86-274

Fatal CHD cases were ascertained by reviewing the state vital records and by a search of the National Death Index. This search was supplemented by reports from the next of kin, and their written permission was sought to review the medical records. Fatal CHD was defined as a fatal MI if confirmed by hospital records or autopsy or as a CHD-related death when recorded on the death certificate if this was the underlying and most plausible cause and there was previous evidence of CHD. We designated as presumed fatal CHD those cases in which CHD was the underlying cause on the death certificate but no records were available. Also included under fatal CHD were cases of sudden death (within 1 hour of the onset of symptoms) with no plausible explanation other than CHD. Stroke was defined according to the National Survey of Stroke criteria 10 by the presence of a typical neurological deficit of sudden or rapid onset, persisting for more than 24 hours or until death. Stroke classifications included ischemic stroke due to thrombotic or embolic occlusion of a cerebral artery or rupture of a vessel resulting in subarachnoid or intraparenchymal hemorrhage. Vascular disease due to traumatic, neoplastic, or infectious processes was excluded. STATISTICAL ANALYSIS Participants contributed person-time from the date of return of the 1976 questionnaire (for those with prevalent diabetes) or from the date of diabetes diagnosis (for those with incident diabetes) until the date of occurrence of MI, the date of death from CHD, or June 1, 1996, whichever came first. Incident cases of CHD were allocated to the exposure status defined in the most recent questionnaire. For comparison of the excess risk of smoking among diabetic and nondiabetic women, incidence rates of CHD were calculated by dividing the number of new cases by the cumulated person-time of follow-up and were adjusted to the age distribution of diabetic and nondiabetic women by direct standardization. Relative risks were calculated as the incidence rate in each smoking category divided by the corresponding rate among never smokers. All relative risks (RRs) were age adjusted, and 95% confidence intervals (CIs) were calculated. The population attributable risk was calculated by using the formula provided by Rothman and Greenland 11 to determine the fraction of cases in the study population that would not have occurred if exposure had not occurred. Pooled logistic regression models with 2-year increments were used to control simultaneously for known CHD risk factors. Most of the covariates were updated biennially, including age ( 50, 50-54, 55-59, 60-64, or 65 years); postmenopausal hormone use (premenopausal status, never used, current use, or past use); alcohol use (0, 0.1-4.9, 5.0-14.9, or 15.0 g/d); duration of diabetes (0-5, 6-10, 11-15, or 15 years); body mass index, calculated as weight in kilograms divided by the square of height in meters (21, 22, 23-24, 25-28, or 29); physical activity ( 1, 1-2, 2-4, 4-7, or 7 h/wk of moderate to vigorous activity); diabetes medication (assessed in the supplementary diabetes questionnaire and in the 1988 and 1994 main questionnaires: none, oral medication only, or insulin use); history of high cholesterol (yes or no); history of high blood pressure (yes or no); and parental history of MI before the age of 60 years (assessed in 1976 and 1984: yes or no). Several dichotomous variables were used for stratified analyses to assess potential effect modification: body mass index ( 25 or 25kg/m 2 ), insulin use (yes or no), parental history of MI (yes or no), postmenopausal hormone use (yes or no), alcohol use (yes or no), duration of diabetes ( 10 or 10 years), physical activity ( 3.5 or 3.5 h/wk), age ( 60 or 60 years), aspirin use (yes or no), and menopause status (premenopausal or postmenopausal). In an additional analysis, we examined the joint effects of smoking and diabetes on the risk of CHD. Values of covariates that were not collected in a given follow-up questionnaire were carried over from the previous questionnaire or carried backward for covariates not recorded at baseline. For example, because alcohol was not recorded in the 1976 and 1978 questionnaires, the 1980 value was carried backward to be used for the 1976 and 1978 cycles. Tests for trend were conducted using the median value for each category of smoking status as a continuous variable. All P values were 2-sided. The SAS statistical software package was used for the analyses. 12 1.25) for past smokers, 1.46 (95% CI, 1.02-2.10) for current smokers of 1 to 14 cigarettes per day, and 2.42 (95% CI, 1.94-3.02) for current smokers of 15 or more cigarettes per day (P.001 for trend). We also compared age-adjusted rates of CHD in women with diabetes with those in nondiabetic women according to smoking status. The age-adjusted incidence rate of CHD among diabetic women was much higher than that of nondiabetic women of similar smoking status (Figure 2). The joint impact of smoking and diabetes status on the risk of CHD was substantial; compared with nondiabetic women who had never smoked, diabetic women who smoked 15 or more cigarettes per day had an age-adjusted RR of 19.01 (95% CI, 15.42-23.45). This RR was attenuated to 7.67 (95% CI, 5.88-10.01) in the multivariate-adjusted model. Among nondiabetic women, the multivariate RR comparing current smokers ( 15 cigarettes per day) with never smokers was 5.13 (95% CI, 4.53-5.80). The corresponding RR among diabetic women was 2.65 (95% CI, 2.06-3.40). The likelihood ratio test and interaction was significant (P.001). The higher RR of CHD of nondiabetic women who smoked compared with diabetic women who smoked can be explained by the much higher baseline risk of diabetic women compared with nondiabetic women. COMMENT We observed a strong positive association between cigarette smoking and CHD among diabetic women. Cigarette smoking amplified the excess risk of CHD associated with type 2 diabetes mellitus. On the other hand, smokers who quit smoking for more than 10 years had a 275

Table 1. Age-Adjusted Characteristics of Diabetic Women According to Smoking Status in 1986* Smoking Status Current Smokers, Cigarettes per Day Characteristic Never Smokers Past Smokers 1-14 15 Total No. 1241 939 157 368 Age, y 62.1 62.1 62.4 60.5 BMI, kg/m 2 29.1 29.4 27.3 27.2 Duration of diabetes, y 9.2 8.6 10.0 9.9 Alcohol consumption, g 2.0 3.4 6.9 5.7 History of high blood pressure 51 57 43 45 History of high cholesterol 22 27 24 25 Current postmenopausal hormone use 18 17 14 14 Insulin use 15 17 15 11 Oral hypoglycemic medication use 20 21 19 17 Parental history of myocardial infarction 23 23 17 24 Physical activity score, h/wk 2.7 2.8 3.0 2.6 Saturated fat intake (energy adjusted), g 21.0 20.8 21.2 22.5 Carbohydrate intake (energy adjusted), g 193.2 188.7 184.0 179.4 Postmenopause status 79 78 76 82 Contraceptive pill (ever use) 41 46 45 46 Aspirin use 73 75 79 70 Vitamin E supplementation 23 19 15 14 *Data are given as percentage of women unless otherwise indicated. The 1986 questionnaire was used as the middle year to represent the overall follow-up period for characteristics of the study population. Based on women who answered the 1986 smoking questionnaire. Data are given as mean values. Insulin use and oral hypoglycemic medication use were based on 1988 data. Table 2. Age- and Multivariate-Adjusted RRs (95% CIs) for Total CHD, Fatal CHD, and Nonfatal MI According to Smoking Status Among Diabetic Women* Smoking Status Current Smokers, Cigarettes per Day P Value Variable Never Smokers Past Smokers 1-14 15 for Trend Person-years 30 752 23 853 3893 9729... Total CHD No. of cases 168 160 27 103... Age-adjusted RR 1.0 1.17 (0.94-1.46) 1.43 (0.95-2.16) 2.35 (1.83-3.02).001 Multivariate-adjusted RR 1.0 1.21 (0.97-1.51) 1.66 (1.10-2.52) 2.68 (2.07-3.48).001 Fatal CHD No. of cases 77 74 13 36... Age-adjusted RR 1.0 1.17 (0.85-1.62) 1.55 (0.86-2.80) 1.87 (1.25-2.80).002 Multivariate-adjusted RR 1.0 1.24 (0.90-1.72) 1.73 (0.95-3.15) 2.11 (1.39-3.19).005 Nonfatal MI No. of cases 91 86 14 67... Age-adjusted RR 1.0 1.17 (0.87-1.57) 1.34 (0.76-2.35) 2.69 (1.95-3.71).001 Multivariate-adjusted RR 1.0 1.19 (0.88-1.61) 1.56 (0.88-2.77) 3.05 (2.19-4.26).001 *The covariates for the multivariate adjustment are age, period, alcohol consumption, duration of diabetes, postmenopausal hormone use, diabetes medication use, body mass index, family history of MI, physical activity, high cholesterol, and high blood pressure. RR indicates relative risk; CI, confidence interval; CHD, coronary heart disease; MI, myocardial infarction; and ellipses, data not applicable. Reference group. risk of developing CHD similar to that of diabetic women who had never smoked. The strengths of the study include the large number of diabetic women and the long duration of followup, which allows the assessment of smoking and CHD risk in different subgroups. The follow-up rate for fatal and nonfatal events was high (approximately 98%), minimizing potential bias due to loss to and unavailability for follow-up. The prospective design minimized selection and recall bias, which can occur in case-control studies. Potential weaknesses should be noted. Some women with diabetes may have been undiagnosed in the cohort because we did not screen for glucose intolerance. However, these cases would not alter the case status of women reporting a diagnosis of diabetes, which was validated in a separate study. 9 The criteria for type 2 diabetes melli- 276

Table 3. Multivariate-Adjusted RR (95% CIs) for Total CHD Incidence According to Smoking Status in Diabetic Women, Stratified by Coronary Covariates* Smoking Status Current Smokers, Cigarettes per Day Variable Never Smokers Past Smokers 1-14 15 BMI, kg/m 2 25 1.0 0.87 (0.46-1.62) 2.48 (1.15-5.30) 1.87 (1.00-3.48) 25 1.0 1.25 (0.98-1.60) 1.35 (0.78-2.32) 2.67 (1.96-3.63) Family history of MI No 1.0 1.09 (0.83-1.43) 1.82 (1.09-3.03) 2.65 (1.92-3.67) Yes 1.0 1.33 (0.87-2.03) 1.51 (0.66-3.45) 1.99 (1.15-3.45) Medication use No 1.0 1.01 (0.76-1.32) 1.71 (1.00-2.92) 2.55 (1.83-3.56) Yes 1.0 1.76 (1.15-2.69) 1.94 (0.92-4.09) 2.29 (1.37-3.83) Alcohol use No 1.0 1.24 (0.92-1.68) 1.27 (0.63-2.55) 2.76 (1.88-4.05) Yes 1.0 1.34 (0.82-2.18) 2.05 (0.97-4.35) 2.96 (1.70-5.15) Duration of diabetes, y 10 1.0 1.09 (0.78-1.52) 1.50 (0.77-2.94) 3.18 (2.20-4.58) 10 1.0 1.25 (0.91-1.72) 1.81 (1.02-3.22) 1.73 (1.12-2.69) Physical activity, h/wk 3.5 1.0 1.13 (0.89-1.44) 1.68 (1.07-2.63) 2.39 (1.80-3.18) 3.5 1.0 1.95 (1.05-3.63) 1.73 (0.57-5.26) 5.81 (2.87-11.76) Age, y 60 1.0 1.24 (0.87-1.76) 1.24 (0.65-2.36) 3.29 (2.34-4.65) 60 1.0 1.18 (0.88-1.57) 2.15 (1.24-3.72) 1.75 (1.13-2.69) Aspirin use No 1.0 1.32 (0.83-2.08) 1.64 (0.68-3.98) 3.65 (2.15-6.19) Yes 1.0 1.13 (0.76-1.68) 1.29 (0.58-2.88) 3.03 (1.94-4.73) Menopause status Current smoking Premenopausal 1.0 1.68 (0.47-5.98) 7.29 (2.51-21.13) Postmenopausal 1.0 1.20 (0.96-1.50) 2.04 (1.58-2.63) Postmenopausal hormone use Current smoking No 1.0 1.16 (0.91-1.56) 2.24 (1.69-2.97) Yes 1.0 1.80 (0.87-3.73) 1.68 (0.57-4.96) P Value for Interaction.20.70.20.60.40.10.03.80.07.20 *The covariates for the multivariate adjustment are the same as those given in the first footnote to Table 2, excluding the stratifying variable. RR indicates relative risk; CI, confidence interval; CHD, coronary heart disease; BMI, body mass index; and MI, myocardial infarction. Reference group. Included treatment with insulin or oral hypoglycemic medications. tus have recently changed, so that those with a glucose level higher than 126 mg/dl ( 7.0 mmol/l) are believed to have diabetes, instead of the 141 mg/dl (7.8 mmol/l) used before the publication of the new criteria in 1997. 13 So, more nondiabetic persons would be classified as having diabetes using the new definition. Nevertheless, inclusion of diabetic persons in the nondiabetic group in our study as a result of using the old definition would have attenuated the associations we observed and is unlikely to change our findings. The smoking assessment was based on self-reports and was not verified by other objective measures. However, reporting of smoking should not be biased in relation to CHD incidence because smoking was assessed before the development of CHD. In addition, because the smoking variable was updated every 2 years, our analyses were able to take into account changes in smoking behavior. Few previous studies have prospectively examined the association between smoking and CHD among diabetic persons. A Finnish prospective study 14 among 313 men and women with type 2 diabetes mellitus did not find smoking to be related to fatal or nonfatal CHD in a univariate logistic regression analysis. Also, in the Whitehall study, 15 smoking was not significantly associated with CHD-related mortality rates among 224 diabetic and glucose-intolerant men. Both studies involved fewer diabetic subjects and had a shorter follow-up than our study; thus, statistical power to detect an association was limited. On the other hand, in the National Health and Nutrition Examination Survey study, 16 CHD-related mortality risk was higher among 492 diabetic smokers compared with never smokers, and in the Multiple Risk Factor Intervention Trial, 17 risk of CVD-related mortality among 5625 diabetic men increased with higher levels of smoking. This was also supported more recently by the results from the United Kingdom Prospective Diabetes Study, 18 in which smoking was a significant risk factor for fatal and nonfatal MI (P=.02) among diabetic women and men in multivariate analyses. Diabetes may increase the risk of CHD through various proposed mechanisms, including lipoprotein changes, increased vascular endothelial injury and permeability, thrombotic disorders, increased oxidative stress, and fibrinolytic factors and platelet activities leading to atheroma formation. 19-21 Smoking may exacerbate these conditions and contribute to a dramatically increased risk 277

Relative Risk of CHD 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 1.00 Never Smokers >15 0.91 11-15 1.08 Quit Smoking, y Current Smokers, Cigarettes per Day Figure 1. Multivariate-adjusted relative risk of coronary heart disease (CHD) according to smoking status and duration of quitting smoking among diabetic women. The vertical bars indicate the 95% confidence intervals. CHD Incidence, per 100 000 Person-Years 1200 1000 800 600 400 200 0 Nondiabetic Women Diabetic Women 48 539 Never Smokers 68 of CHD among diabetic persons by a combination of shortterm effects (coronary artery spasm, arrythmias, and increased platelet aggregation) and long-term effects (increased triglyceride levels, decreased high-density lipoprotein levels, and other metabolic effects that lead to atherogenesis) 19,22 on the cardiovascular system. Smoking is also thought to increase insulin resistance and aggravate metabolic disturbances among diabetic persons. 23,24 Targher et al, 25 for example, found among 40 diabetic patients that insulin resistance was markedly aggravated among smokers. In previous studies, smoking 25 cigarettes per day or more, compared with never smoking, was associated with a higher risk of developing diabetes among women (RR, 1.42; 95% CI, 1.18-1.72) 26 and men (RR, 1.94; 95% CI, 1.25-3.03). 27 Our results also indicate that diabetic women who smoked 15 or more cigarettes per day had an 84% higher risk of developing stroke compared with never smokers. These results are consistent with earlier findings 9 that smoking amplifies the risk of stroke among diabetic women. Quitting smoking and maintaining cessation for more than 10 years seem to substantially reduce the high risk of developing CHD among diabetic women who smoked. The benefits of smoking cessation are associated with total 623 Past Smokers 6-10 1.32 1-5 144 1.40 792 1-14 1.68 223 15 1-14 15 Current Smokers, Cigarettes per Day 2.68 1114 Figure 2. Age-adjusted coronary heart disease (CHD) incidence rates (per 100000 person-years) among women with and without diabetes according to smoking status. mortality rate, 28 with CHD and stroke incidence among the Nurses Health Study and general populations, 29-32 and, more recently, with CHD risk in the United Kingdom Prospective Diabetes Study cohort of diabetic persons. 18 The United Kingdom Prospective Diabetes Study found that, compared with never smokers, past smokers were at lower risk of nonfatal and fatal MI (RR, 1.27) than current smokers (RR, 1.74). However, that study did not provide detailed analysis of past smokers according to the duration of quitting and its association with CHD risk. The American Diabetic Association 33 recently emphasized the importance of targeted smoking cessation programs for diabetic persons, calling for health care providers to (1) routinely assess tobacco use among diabetic persons, (2) counsel on smoking prevention and cessation, and (3) routinely implement smoking cessation guidelines. Although smoking rates were slightly lower among the diabetic women in our study compared with the nondiabetic population, it is alarming that others found smoking rates among diabetic persons to be similar to 24 or even higher than 17,34 those of nondiabetic persons. However, individuals with diabetes seem to be more receptive to their physician s advice and to the prospect of smoking cessation. 35,36 Smoking cessation may have an important effect on CHD risk reduction among diabetic persons compared with the effects reported with cholesterol lowering or high blood pressure treatment. Clinical trials to lower cholesterol levels among diabetic persons achieved 25% to 55% reduction in the risk of major CHD-related events, 37,38 and tight blood pressure control achieved 21% reduction in the risk of fatal and nonfatal MI and sudden death (although the results were not statistically significant). 39 Our results suggest that the risk of CHD among diabetic women who smoke could have been reduced by about 54% if they had not smoked. In the overall diabetic population, which comprises 20% smokers, the population attributable risk due to current smoking was 19%. Our findings have important clinical and public health implications and provide strong support for the American Diabetic Association recommendations. Given that cigarette smoking is such a strong, yet modifiable, risk factor for CHD among diabetic individuals, physicians should discourage their diabetic patients from smoking. Accepted for publication May 8, 2001. This study was supported by research grants HL24074, HL34594, and CA87969 from the National Institutes of Health, Bethesda, Md; and a research award from the American Diabetic Association, Alexandria, Va (Dr Hu). We thank Al Wing for his support and help and the subjects who participated in the Nurses Health Study. Corresponding author: Wael K. Al-Delaimy, MD, PhD, Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115 (e-mail: wael @hsph.harvard.edu). REFERENCES 1. Walters D, Gatling W, Houston A, Mulle M, Julious S, Hill R. Mortality in diabetic subjects: an eleven-year follow-up of a community-based population. Diabet Med. 1994;11:968-973. 278

2. Wei M, Mitchell B, Haffner S, Stern M. Effects of cigarette smoking, diabetes, high cholestrol, and hypertention on all-cause mortality and cardiovascular disease mortality in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1996;144:1058-1065. 3. Sowers J. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998;158:617-621. 4. Barrett-Connor E, Cohn B, Wingard D, Edelstein S. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than men? JAMA. 1991;265:627-631. 5. Fuller J, Steven L, Wang S. International variations in cardiovascular mortality associated with diabetes mellitus: the WHO multinational study of vascular disease in diabetes. Ann Med. 1996;28:319-322. 6. US Department of Health and Human Services. Health Consequences of Smoking Cardiovascular Disease: A Report of the Surgeon General. Rockville, Md: Office on Smoking and Health, Public Health Service, US Dept of Health and Human Services; 1983. 7. Eschwege E, Balkau B, Fontbonne A. The epidemiology of coronary heart disease in glucose-intolerant and diabetic subjects. J Intern Med. 1994;236:5-11. 8. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057. 9. Manson J, Colditz G, Stampfer M, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147. 10. Walker A, Robins M, Weinfeld F. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl 1):I13-I44. 11. Rothman K, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:295. 12. SAS Institute Inc. SAS User s Guide: Basics (Version 5). Cary, NC: SAS Institute Inc; 1985. 13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197. 14. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non insulindependent diabetes. Circulation. 1993;88:1421-1430. 15. Fuller J, Shipley M, Rose G, Jarrett R, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ. 1983; 287:867-870. 16. Ford E, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Am J Epidemiol. 1991;133: 1220-1230. 17. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444. 18. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828. 19. Dean J, Matthews S, Dolben J, Carolan G, Luzio S, Owens D. Cholestrol rich apo B containing lipoproteins and smoking are independently associated with macrovascular disease in normotensive NIDDM patients. Diabet Med. 1994;11:740-747. 20. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524. 21. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15:1835-1843. 22. Jonas M, Oates J, Ockene J, Hennekens C. Statement on smoking and cardiovascular disease for health care professionals: AHA position statement. Circulation. 1992;86:1664-1669. 23. Facchini F, Hollenbeck C, Jeppesen J, Chen Y, Reaven G. Insulin resistance and cigarette smoking. Lancet. 1992;339:1128-1130. 24. Haire-Joshu D, Glasgow R, Tibbs T. Smoking and diabetes. Diabetes Care. 1999; 22:1887-1898. 25. Targher G, Alberiche M, Zenere M, Bonadonna R, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:3619-3624. 26. Rimm E, Manson J, Stampfer M. Cigarette smoking and the risk of diabetes in women. Am J Public Health. 1993;83:211-214. 27. Rimm E, Chan J, Stampfer M, Colditz G, Willett W. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ. 1995;310:555-559. 28. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. Ann Intern Med. 1993;119:992-1000. 29. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987; 317:1303-1309. 30. Kawachi I, Colditz G, Stampfer M, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994;154:169-175. 31. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269:232-236. 32. US Department of Health and Human Services. The Health Benefits of Smoking Cessation. Rockville, Md: Centers for Disease Control; 1990. 33. American Diabetic Association. Smoking and diabetes. Diabetes Care. 2000;23: 93-94. 34. Uusitupa M, Niskanen L, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1184. 35. Ruggiero L, Rossi JS, Prochaska JO, et al. Smoking and diabetes: readiness for change and provider advice. Addict Behav. 1999;24:573-578. 36. Wilkes S, Evans A. A cross-sectional study comparing the motivation for smoking cessation in apparently healthy patients who smoke to those who smoke and have ischaemic heart disease, hypertension or diabetes. Fam Pract. 1999;16: 608-610. 37. Goldberg RB, Mellies MJ, Sacks FM, et al, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519. 38. Payorala K, Pedersen T, Kjekshus J, Faergeman O, Olsson A, Thorgeirsson G. Cholestrol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care. 1997;4:614-620. 39. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:B. 279